95%Confidence
0Views
FDASource
2026-03-11Date
Summary
FDA recall of ophthalmic strips due to sterility issues indicates significant quality control failures at the contract manufacturer Omni Lens. This poses regulatory and reputational risks for the distributor HUB Pharmaceuticals and may impact supply in the diagnostic eye care market.
Actionable: Monitor HUB Pharmaceuticals for potential supply disruptions and regulatory actions, and consider alternative suppliers for fluorescein sodium strips.
AI Confidence: 95%
Data Points
firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productBioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 - Samrudhhi, Opp. Sakar-III, Navrangpur
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now